[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-459463-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-459463-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","long-term-implantable-biventricular-assist-device-support-experience-of-6-cases","Long-Term Implantable Biventricular Assist Device Support - Experience of 6 Cases","","Long-term outcomes of implantable biventricular assist device (BiVAD) support were retrospectively reviewed for six patients treated at Osaka University Hospital between January 2010 and March 2019. The study evaluated patient characteristics, device selection for right ventricular assist (RVAD) use, and major adverse events. Mean age was 31±11 years with 33% male. Survival at 1 and 3 years was 83% and 67%, with multiple complications including stroke, hemolysis/pump thrombosis, heart failure recurrence, and device-related infection in a subset.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/long-term-implantable-biventricular-assist-device-support-experience-of-6-cases/459463/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/long-term-implantable-biventricular-assist-device-support-experience-of-6-cases/459463.png","ImageObject",300,407,{"name":42,"@type":43},"Margaret","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",16,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How many patients were included, and when were they treated?","Question",{"text":63,"@type":64},"Six patients underwent BiVAD implantation at Osaka University Hospital between January 2010 and March 2019.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the survival rates after BiVAD implantation?",{"text":68,"@type":64},"Survival was 83% at 1 year and 67% at 3 years after BiVAD implantation.",{"name":70,"@type":61,"acceptedAnswer":71},"Which complications occurred during follow-up?",{"text":72,"@type":64},"Stroke occurred in 3 patients, and hemolysis or pump thrombosis occurred in 3 patients; heart failure occurred in 3 patients, and device-related infection occurred in 1 patient.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},459463,1791031513,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},137451207643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Circulation Reports  \nCirc Rep 2026; 8: 103–109 doi:10.1253/circrep.CR-25-0224  \nORIGINAL ARTICLE Cardiovascular Surgery  \nLong-Term Implantable Biventricular Assist Device Support  \n―Experience of 6 Cases―  \nShusuke Imaoka, MD; Shunsuke Saito, MD, PhD; Daisuke Yoshioka, MD, PhD; Takuji Kawamura, MD, PhD; Ai Kawamura, MD, PhD; Shin Yajima, MD, PhD; Ryohei Matsuura, MD, PhD; Yusuke Misumi, MD, PhD; Shigeru Miyagawa, MD, PhD  \nBackground: Managing heart failure complicated by severe right heart failure with implantable mechanical circulatory support remains a significant challenge. One therapeutic strategy is biventricular assist device (BiVAD) support, typically involving the off-label use of 2 implantable left ventricular assist devices (LVADs) . Because the available data of implantable BiVAD support remain limited, we reviewed the data for 6 patients on implantable BiVAD support.  \nMethods and Results: Between January 2010 and March 2019, 6 patients underwent BiVAD implantation at Osaka University Hospital. Their mean age was 31± 11 years, and 2 (33%) were male. The right ventricular assist devices (RVADs) utilized were Jarvik2000 (Jarvik Heart, NY, USA) in 4 patients (67%), and HVAD (HeartWare, Framingham, MA, USA) in 2 patients (33%) . The survival rates at 1 and 3 years after BiVAD implantation were 83% and 67%, respectively. Of the 6 patients, 4 underwent heart transplantation at 553, 709, 791, and 1,245 days, respectively, following RVAD implantation; 2 patients died during follow-up at 280 and 511 days, respectively, after RVAD implantation. Stroke occurred in 3 patients. Hemolysis or pump thrombosis occurred in 3 patients. Heart failure occurred in 3 patients. Device-related infection occurred in 1 patient.  \nConclusions: Although implantable BiVAD support provided a feasible bridge to transplantation with favorable survival, the high incidence of complications indicates that significant challenges remain in optimizing patient outcomes and emphasizes the necessity for RV-specific device development.  \nKey Words: Biventricular assist device; Left ventricular assist device; Right ventricular assist device  \n\n| C\u003Cbr>ardiovascular medicine for heart failure (HF) has made significant progress,1,2 and for patients in whom HF does not improve with medical therapy,\u003Cbr>left ventricular assist devices (LVADs) play a crucial role in clinical management. However, managing HF complicated by severe right HF with implantable mechanical circulatory support remains a significant clinical challenge.3–6 One therapeutic strategy for such cases of severe biventricular failure is biventricular assist device (BiVAD) support, typically involving the off-label use of 2 LVADs. Although several studies have reported clinical outcomes associated with implantable BiVAD support, the available data remain limited.7,8 We experienced 6 cases of BiVADimplantation at Osaka University Hospital, and the present study is our retrospective review of those patients, focusing on their preoperative characteristics, clinical outcomes, and adverse events. | Methods\u003Cbr>Patients\u003Cbr>Between January 2010 and March 2019, 6 patients underwent BiVAD implantation at Osaka University Hospital. Devices for RVAD was purchased through our research grant and BiVAD implantation was approved by the Osaka University School of Medicine. The mean age of the patients was 31±11 years, and 2 (33%) were male. The underlying etiologies were fulminant myocarditis in 3 (50%), endstage hypertrophic cardiomyopathy in 1 (17%), arrhythmogenic right ventricular cardiomyopathy in 1 (17%), and cardiac sarcoidosis in 1 patient (17%) . The interagency registry for mechanically assisted circulatory support (INTERMACS) profiles were Bridge-to-Bridge in 2 patients (33%), Profile 1 in 3 patients (50%), and Profile 2 in 1 patient (17%) (Table) .\u003Cbr>All patients and their families provided informed consent |\n| --- | --- |\n\nReceived September 9, 2025; revised manuscript received September 14, 2025; ac","cbCaijs8MdTB2HL4","https://ap.wps.com/l/cbCaijs8MdTB2HL4","pdf",1058108,"English","# Background\n# Methods and Results\n## Patients and devices\n## Outcomes and adverse events\n# Conclusions\n# Key words","[{\"question\":\"How many patients were included, and when were they treated?\",\"answer\":\"Six patients underwent BiVAD implantation at Osaka University Hospital between January 2010 and March 2019.\"},{\"question\":\"What were the survival rates after BiVAD implantation?\",\"answer\":\"Survival was 83% at 1 year and 67% at 3 years after BiVAD implantation.\"},{\"question\":\"Which complications occurred during follow-up?\",\"answer\":\"Stroke occurred in 3 patients, and hemolysis or pump thrombosis occurred in 3 patients; heart failure occurred in 3 patients, and device-related infection occurred in 1 patient.\"}]","Long-Term Implantable Biventricular Assist Device Support - Experience of 6 Cases | PDF",1790755990,18]